The interface of pancreatitis and early pancreatic cancer progression – In depth analysis of the novel, spontanous pancreatic cancer mouse model Cpa1 N256K – KC

胰腺炎与早期胰腺癌进展的界面 â 深入分析新型自发性胰腺癌小鼠模型 Cpa1 N256K â KC

基本信息

项目摘要

Pancreatic cancer will be the second most common cause of death of all cancers in 2030. Amongst others chronic pancreatitis is a risk factor for the development of pancreatic cancer and the risk increase is highest in inherited chronic pancreatitis. In the last decades several genetic associations in chronic pancreatitis have been described for example with mutations in the cationic trypsinogen gene (PRSS1) or the serine protease inhibitor, Kazal type 1 (SPINK1). In 2013 a novel association with mutations in carboxypeptidase A1 (CPA1) with an early onset of the disease was reported. Recently, a novel animal model of chronic pancreatitis harbouring a knock in of the common p.N256K mutation was generated and presented with a spontaneous phenotype of chronic pancreatitis. This model is ideal to further elucidate the early mechanisms of inflammatory cues in carcinogenesis and for this purpose we crossbred Cpa1N256K with KrasG12D mutated mice (KC) to generate a novel model of pancreatic cancer development. In this model we will focus on early acinar events in vivo and in primary acinar cells as well as by overexpression of mutated CPA1 in murine pancreatic PanIN cells. The experiments will focus on events induced by endoplasmatic reticulum stress and on known pathways and immune phenotypes relevant for pancreatic cancer development on the level of the transcriptom and proteom. On the long-term identified pathways or immune phenotypes will be targeted to prevent the development of tumour stroma and tumour development.
到2030年,胰腺癌将成为所有癌症中第二大常见死因。在其他疾病中,慢性胰腺炎是胰腺癌发展的一个危险因素,而遗传性慢性胰腺炎的风险增加最高。在过去的几十年里,慢性胰腺炎的一些遗传关联已经被描述,例如阳离子胰蛋白酶原基因(PRSS1)或丝氨酸蛋白酶抑制剂Kazal型1 (SPINK1)的突变。2013年,有报道称羧基肽酶A1 (CPA1)突变与该疾病的早期发病有新的关联。最近,一种新的慢性胰腺炎动物模型产生了常见的p.N256K突变的敲入,并呈现出慢性胰腺炎的自发表型。该模型是进一步阐明炎症线索在癌变中的早期机制的理想模型,为此,我们将Cpa1N256K与KrasG12D突变小鼠(KC)杂交,以产生一种新的胰腺癌发展模型。在这个模型中,我们将关注体内和原代腺泡细胞中的早期腺泡事件,以及小鼠胰腺PanIN细胞中突变CPA1的过表达。实验将集中在内质网应激诱导的事件,以及转录和蛋白质组水平上与胰腺癌发展相关的已知途径和免疫表型。对长期确定的途径或免疫表型将有针对性地防止肿瘤基质的发展和肿瘤的发展。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Professor Dr. Jonas Rosendahl其他文献

Professor Dr. Jonas Rosendahl的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Professor Dr. Jonas Rosendahl', 18)}}的其他基金

Regional replication, refinement and functional characterisation of GWAs variants in alcoholic and non-alcoholic chronic pancreatitis
酒精性和非酒精性慢性胰腺炎 GWA 变异的区域复制、细化和功能表征
  • 批准号:
    321033801
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
    Research Grants
Genetic Risk contribution to Alcoholic chronic Pancreatitis (GRAP study)
遗传风险对酒精性慢性胰腺炎的影响(GRAP 研究)
  • 批准号:
    181008647
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:
    Research Grants
Genetische Analyse einer PARtizipation des PAR2, PAR4 und der TPST2 bei chronischer Pankreatitis
PAR2、PAR4、TPST2参与慢性胰腺炎的基因分析
  • 批准号:
    136110043
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
    Research Grants

相似海外基金

Real Time Metabolic Imaging to Interrogate Early Detection and Prevention of Pancreatic Cancer
实时代谢成像探讨胰腺癌的早期检测和预防
  • 批准号:
    10744576
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
R21 MPI microRNA directed therapy for treating early stage pancreatic cancer
R21 MPI microRNA 定向疗法治疗早期胰腺癌
  • 批准号:
    10577609
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programs
通过风险分层社区参与计划验证用于早期检测胰腺癌的新型成像和分子测试
  • 批准号:
    10640704
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY
免疫治疗引起的自身免疫性疾病的新型体液和细胞生物标志物
  • 批准号:
    10593224
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Biomarker Validation in Pancreatic Cystic Neoplasms
胰腺囊性肿瘤的生物标志物验证
  • 批准号:
    10722347
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Multi-site Gastrointestinal Cancer Detection by Stool DNA Methylation
通过粪便 DNA 甲基化进行多部位胃肠癌检测
  • 批准号:
    10443018
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Quantitative characterization of the liver-pancreas axis in diabetes via multiparametric magnetic resonance elastography
通过多参数磁共振弹性成像定量表征糖尿病肝胰轴
  • 批准号:
    10718333
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Long term efficacy and safety of orlistat for type 1 hyperlipoproteinemia: a randomized, double-blind, placebo-controlled trial
奥利司他治疗 1 型高脂蛋白血症的长期疗效和安全性:一项随机、双盲、安慰剂对照试验
  • 批准号:
    10570530
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Combining Machine Learning and Nanofluidic Technology for The Multiplexed Diagnosis of Pancreatic Adenocarcinoma
结合机器学习和纳流体技术进行胰腺癌的多重诊断
  • 批准号:
    10613226
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了